Karyopharm Announces FDA Approval of XPOVIOĀ® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Claimed Company
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions read more
Sharon Shacham Ph.D., M.B.A. ā Co-Founder, Co-Chairman of Scientific Advisory Board, President & Chief Scientific Officer at Karyopharm Therapeutics
Executive Bio
Dr. Sharon Shacham, Ph.D., MBA, Co-Founded Karyopharm Therapeutics Inc. in 2008 and has been its Chief Scientific Officer and President since October 2010 and since December 2013 respectively. Dr. Shacham served as the President of Research & Development at Karyopharm Therapeutics Inc. since December 2012 until December 2013. She served as President and Chief Executive Officer at Karyopharm Therapeutics Inc. from October 2010 to January 2011 and its Head of Research & Development from October 2010 to December 2012. Dr. Shacham has led Karyopharm's scientific progress since inception. Prior to joining Karyopharm, from 2000 to April 2009, she was Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., which underwent liquidation proceedings in 2009 and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc. which merged into Epix Pharmaceuticals in 2006, where she led the company's efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials. She also served as Vice President of Drug Development and Product Leadership of EPIX Pharmaceuticals Inc. Dr. Shacham serves as the Co-Chairman of Scientific Advisory Board at Karyopharm Therapeutics Inc. She served as Director of Karyopharm Therapeutics Inc. Dr. Shacham has published numerous scientific papers. She received a B.Sc. in Chemistry (Magna Cum Laude), a Ph.D. thesis on the in silico modeling of GPCRs (Biochemistry) and Biophysics and an MBA from Tel Aviv University.
Key Executives
Name
Title
Salary
Total Comp Total Compensation includes both short-term and long-term benefits, option grants, salary, bonuses, company perks, etc. that can be used to determine financial benefits. An executive may or may not realize all of the Total Co mpensation during their tenure at the Company. Values of the benefits may change over time.
Co-Founder, Co-Chairman of Scientific Advisory Board, President & Chief Scientific Officer
$415k
$1.35M
Executive Team Culture Ratings from Karyopharm Therapeutics Employees
TOP
15%
Karyopharm Therapeutics' Executive Team scores in the Top 15%
of similar sized companies on Comparably
of similar sized companies on Comparably
Karyopharm Therapeutics' Executive Team at a Glance
Based on 178 ratings, Karyopharm Therapeutics' employees are very satisfied with their Executive Team and give them an āA-ā or 80/100. On average, Men provided higher ratings for their Executive Team compared to Women. Also, the Other department thinks more highly of the Executive Team relative to the Clinical Operations department.
Karyopharm Therapeutics' Executive Team ranks in the Top 20% of other companies in Boston and Top 15% of other companies on Comparably that also have 201-500 Employees.
×